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Loss of DNA mismatch repair is a common ﬁnding in hereditary nonpolyposis colon cancer as well as in many types of
sporadic human tumours. DNA mismatch repair-deﬁcient cells have been reported to be resistant to many chemotherapeutic
agents and to radiotherapy, and to have the potential of rapidly acquiring additional mutations leading to tumour progression.
Photodynamic therapy is a new treatment modality using light to activate a photosensitiser that preferentially localises in
tumour cells. An oxygen dependent photochemical reaction ensues, resulting in selective tumour necrosis. The effect of loss of
DNA mismatch repair activity on the sensitivity to photodynamic therapy was tested using pairs of cell lines proﬁcient or
deﬁcient in mismatch repair due to loss of either MLH1 or MSH2 protein function. Cells were incubated with the
photosensitiser 5,10,15,20-meta-tetra(hydroxyphenyl)chlorin and exposed to laser light at 652 nm with various optical doses
ranging from 0–1 J cm
72. Cell survival was assessed using the clonogenic assay. Loss of MLH1 or MSH2 function was not
associated with resistance to photodynamic therapy. MCF-7 cells repeatedly treated with photodynamic therapy expressed
parental levels of MLH1, MSH2, MSH6, and PMS2. DNA mismatch repair-deﬁcient and -proﬁcient cells showed similar
subcellular distributions of meta-tetra(hydroxyphenyl)chlorin as analysed by laser scanning and ﬂuorescence microscopy.
Therefore, repeated exposure of tumour cells to photodynamic therapy does not seem to result in loss of DNA mismatch
repair, and loss of mismatch repair, in turn, does not seem to contribute to resistance to photodynamic therapy. Our results
suggest recommending photodynamic therapy as a strategy for circumventing resistance due to loss of DNA mismatch repair.
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DNA mismatch repair (MMR) proteins repair mispaired DNA
bases and have an important role in maintaining the integrity of
the genome (Modrich, 1997). Loss of MMR is the genetic basis
for the hereditary nonpolyposis colon cancer syndrome and is a
common ﬁnding in a variety of sporadic human tumours. Recent
studies have documented that loss of MMR is an important
mechanism of resistance to a variety of clinically important drugs,
including cisplatin (Aebi et al, 1996; Fink et al, 1996) and the
topoisomerase II poisons (Fedier et al, 2001). This is due, in part,
to the fact that the MMR system can recognise and bind to various
types of adducts in DNA. In addition, the genomic instability that
accompanies loss of MMR can increase the rate of mutation in
coding or regulatory sequences of other genes whose products
may play central roles in determining tumour cell sensitivity to
drugs. Loss of MMR has been reported in tumour cell lines selected
by repeated treatments for resistance to cisplatin, methylating
agents and doxorubicin (Aebi et al, 1996; Brown et al, 1997).
Although the reports are controversial there is some evidence that
MMR-deﬁcient cells are also resistant to ionising radiation (Fritzell
et al, 1997; Xu et al, 2001). The development of drug resistance
during chemotherapy of initially chemosensitive tumours is a
frequent problem in clinical oncology, since it may lead to tumour
progression and ﬁnally to the death of the patient. Thus, ﬁnding
new treatment modalities effective against MMR-deﬁcient tumour
cells is of the utmost clinical importance.
Photodynamic therapy (PDT) is being evaluated as an alter-
native treatment option for chemotherapy-resistant tumours
(Canti et al, 1995). PDT uses laser light of appropriate wave-
length and energy to activate a systemically applied
photosensitiser that concentrates preferentially in malignant
tissues. A photochemical reaction ensues, leading to selective
tumour necrosis (Dougherty et al, 1975). 5,10,15,20-meta-tetra-
(hydroxyphenyl)chlorin (m-THPC) is a neutral lipophilic
second-generation photosensitiser with an absorption maximum
at 652 nm. Confocal laser scanning ﬂuorescence microscopy
studies of m-THPC in vitro have shown a diffuse distribution
of the drug in the cytoplasm (McNair et al, 1997). Although
there is no localisation of the photosensitiser within the
nucleus, a low level of potentially mutagenic DNA damage
could occur, depending on the photosensitiser, the cellular
repair mechanisms and the affected genes (Oleinick and Evans,
1998). Indeed, PDT has been reported to result in DNA lesions
such as single-strand breaks and alkali-labile sites, DNA protein
crosslink-correlation and DNA degradation as well as in chromo-
some aberrations (Evans et al, 1997; Oleinick and Evans,
1998). One major advantage of PDT over other treatment
modalities is that it can be safely repeated several times
(Hornung et al, 1998). Moreover, PDT has been reported to
be effective in multi-drug resistant cell lines (Canti et al, 1995).
In the current study, we sought to determine whether loss of
MMR affects the sensitivity of tumour cells to PDT. We report
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and that repeated exposure of cells to PDT in turn, does not result
in loss of MMR, meaning that PDT can be recommended for use
in tumours deﬁcient in MMR.
MATERIALS AND METHODS
Cell lines
The MLH1-deﬁcient human colorectal adenocarcinoma cell line
HCT116 was obtained from the American Tissue Culture Collec-
tion (ATCC CCL 247, Manassas, VA, USA). Sublines
complemented with chromosome 3 (clone HCT116/3-6, identiﬁed
here as HCT116+ch3) or chromosome 2 (clone HCT116/271,
identiﬁed here as HCT116+ch2) were obtained from Drs CR
Boland and M Koi (Koi et al, 1994) as were the MSH2-deﬁcient
human endometrial adenocarcinoma cell line HEC59 and a subline
complemented with chromosome 2 (HEC59+ch2). HCT116 cells
contain a hemizygous mutation in MLH1 resulting in a truncated,
nonfunctional protein (Boyer et al, 1995). Parental HEC59 cells
have been shown to contain a frameshift mutation in one allele
and a truncating mutation in the second allele of MSH2 and to
be deﬁcient in repair activity (Umar et al, 1997). The chromo-
some-complemented sublines HCT116+ch3 and HEC59+ch2 are
competent in MMR. Both cell lines were grown in Iscove’s modi-
ﬁed Dulbecco’s medium (Life Technologies, Basel, Switzerland)
supplemented with 2 mML -glutamine and 10% heat-inactivated
foetal bovine serum (GIBCO, Basel, Switzerland). Geneticin
(400 mgm l
71 for HCT116+ch2 and HCT116+ch3 and
600 mgm l
71 for HEC59+ch2) (Life Technologies) was added to
medium to maintain the chromosome-complemented lines, but
all the experiments were carried out in its absence. The absence
and presence of expression of MLH1 in HCT116+ch2 and
HCT116+ch3 as well as expression of MSH2 in HEC59 and
HEC59+2 were veriﬁed by immunoblot analysis (data not shown).
The oestrogen dependent human breast cancer cell line MCF-7,
proﬁcient in MMR, was cultured in Opti-MEM (GIBCO) supple-
mented with 10% foetal bovine serum, 25 IE ml
71 penicillin
(GIBCO) and 25 mg ml
71 streptomycin (GIBCO). The cell lines
tested negative for contamination with Mycoplasma spp and
cultured as monolayers in a 95% air/5% CO2 atmosphere at
378C. All cell lines used in the experiments form well-deﬁned indi-
vidual colonies when seeded sparsely on standard tissue culture
plates.
Reagents
The porphyrin-based photosensitiser 5,10,15,20-meta-tetra (hydro-
xyphenyl)chlorin (m-THPC, Foscan
1) with a molecular weight of
680 Daltons was provided by SCOTIA Pharmaceuticals Ltd (Stir-
ling, UK). This second-generation photosensitiser has recently
been approved by the European Medicine Evaluation Agency for
treatment of head and neck cancer. The absorption maximum of
m-THPC is at 652 nm. m-THPC was dissolved in a recommended
solution of ethanol:polyethylene-glycol:water (20:30:50) to a
concentration of 5 mg per 10 ml, and stored at 48C in the dark.
6-Thioguanine was purchased from Sigma (Buchs, Switzerland)
and dissolved immediately before use in 0.9% saline.
PDT experiments
PDT experiments were carried out under dimmed room light as
follows. Cells growing in log phase were harvested with EDTA-
trypsin and washed with phosphate-buffered saline (PBS). Either
2000 MLH1-proﬁcient or -deﬁcient cells (HCT116), or 10000
MSH2-proﬁcient or -deﬁcient cells (HEC59) from a single-cell
suspension were seeded into 60 mm tissue culture dishes. After
24 h, 0.1 mgm l
71 m-THPC diluted in tissue culture medium
was added to the dishes and cells were incubated with m-THPC
for 24 h. Cells not exposed to either m-THPC or laser light were
used as controls. Then, cells were exposed to laser light at a wave-
length of 652 nm generated by a diode laser (Applied Optronics
Corp., South Plainﬁeld, NJ, USA) and an energy of 25 mW as veri-
ﬁed by a power meter (Fieldmaster Coherent Inc., Santa Clara,
USA). The light was conducted through a laser ﬁbre terminated
by a front lens light diffuser to the site of irradiation. The optical
dose (J cm
72) is deﬁned as the ﬂuence rate (W cm
72) multiplied
by the exposure time in seconds. Irradiation times for the colorec-
tal and the endometrial cancer cells were 0, 7, 14, 28, 42 or 56 s,
resulting in optical doses of 0, 0.125, 0.25, 0.5, 0.75 or 1 J cm
72
at a ﬂuence rate of 36 mW cm
72. The cells were then washed,
fresh medium was added and the cells were allowed to proliferate
for 10 days.
Repetitive PDT exposure of MCF-7 cells
MCF-7 breast cancer cells (10
6) growing in log phase were seeded
into 60 mm tissue culture dishes. After 24 h, m-THPC was added
to a ﬁnal concentration of 0.1 mgm l
71 and incubated for 24 h in
the dark, followed by illumination for 5 min with a ﬂuence rate of
25 mW cm
72 resulting in an optical dose of 2.12 J cm
72. This
PDT dose resulted in a survival fraction of approximately 10
74.
Surviving cells were allowed to proliferate to a density of 10
6 cells,
and the experiment was repeated for a total of ﬁve times. The repeti-
tion was restricted to ﬁve times due to the fact that from the
clinician’s point of view it is very unlikely that recurrent tumours will
be treated more than ﬁve times with the same treatment modality.
Clonogenic assay
Cell survival was assessed by means of the clonogenic assay 10 days
after PDT exposure. Cells were ﬁxed with 25% acetic acid in etha-
nol and stained with Giemsa. Colonies of at least 50 cells were
scored visually. Each experiment was performed at least three times
using triplicate cultures for each optical dose. Cell survival was
expressed as a fraction of treated to untreated cells (survival frac-
tion, SF) at a relative plating efﬁciency of 0.5% for the HCT116
and 0.3% for the HEC59 cell lines.
Immunoblot analysis
Parental and PDT-treated MCF-7 cells were harvested as described
before and lysed on ice in 150 mM NaCl containing 5 mM EDTA,
1% Triton X-100, 10 mM Tris/HCl (pH 7.4), 5 mM dithiothreitol,
0.1 mM phenylmethylsulphonyl ﬂuoride and 1 mgm l
71 aprotinin,
followed by centrifugation at 14000 g for 20 min at 48C. The
protein amount was determined using the Bio-Rad protein assay
dye (Bio-Rad, Glattbrugg, Switzerland). After centrifugation,
50 mg protein were denaturated by boiling at 958C for 5 min in
an equal volume of 130 mM Tris/HCl (pH 6.8) containing 20%
glycerol, 4.6% sodium dodecyl sulphate (SDS) and 0.02% bromo-
phenol blue. The proteins were separated using SDS–PAGE on a
7.5% gel followed by blotting onto a polyvinylidene diﬂuoride
membrane (Amersham Pharmacia Biotech, Buckinghamshire,
UK). The MMR proteins were detected using anti-MLH1 (clone
G168-728, PharMingen, Heidelberg, Germany), anti-MSH2 (clone
FE11, Calbiochem, Lucerne, Switzerland), anti-MSH6 (provided
by Dr J Jiricny) and anti-PMS2 (clone A16-4, PharMingen). b-
tubulin was used as a loading control. The monoclonal antibody
G168-728 was generated with a full-length MLH1 protein, whereas
clone FE11 is a mouse monoclonal antibody generated with a
carboxyl-terminal fragment of the MSH2 protein. The polyclonal
anti-MSH6 is directed against the full-length protein. The mono-
clonal antibody A16-4 was prepared with a carboxyl-terminal
fragment of the PMS2 protein. After washing the blots, horseradish
peroxidase-conjugated antimouse antibody (Amersham Life
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visualised by enhanced chemiluminescence (Amersham Life
Science).
Subcellular drug distribution and kinetics of drug uptake
A confocal laser scanning microscope (Leica TCS 4D, Glattbrugg,
Switzerland) equipped with an Argon Krypton laser was used to
investigate subcellular photosensitiser distribution. HCT116+ch2
and HCT116+ch3 cells were grown on cover slides and incubated
for 24 h with 0.1 mgm l
71 m-THPC. The dye was excited at
488 nm and ﬂuorescence was detected above 590 nm with a long-
pass ﬁlter. Kinetics of drug uptake were studied using a
ﬂuorescence microscope (Leitz DMRBE, Leica, Glattbrugg, Switzer-
land) equipped with a computer-controlled charge coupled device
camera (Photometrics Ltd., Tucson, AZ, USA). A 530 out of
595 nm bandpass ﬁlter and a 615 nm longpass ﬁlter were used
for excitation and for detection of emission, respectively. Five
micrographs per slide were taken and two cells per picture were
analysed. Fluorescence intensity was quantiﬁed (counts per pixel)
as a function of the incubation time using IPLab Spectrum soft-
ware (Scanalytics, Fairfax, VA, USA). Experiments were repeated
ﬁve times.
Statistical analysis
Mean+s.d. values were calculated for all data sets. The two-sided
paired t-test was used to compare the effect of loss of MLH1 or
MSH2 on PDT sensitivity. IC50-values were calculated by log-linear
interpolation. P50.05 was considered to be a statistically signiﬁ-
cant difference.
RESULTS
Clonogenic cell survival after PDT
A point investigated was whether the sensitivity of tumour cells to
PDT is affected by the MMR status. 6-Thioguanine, to which
repair-deﬁcient cells were, as expected, 4.2- (IC50; HCT116+ch2)
and 5.6-fold (IC50; HEC59) more resistant than the repair-proﬁcient
sublines, was included as a control. Figure 1 shows the survival
curves for the MLH1-deﬁcient HCT116+ch2 and the MSH2-deﬁ-
cient HEC59 cells as well as the respective repair-proﬁcient
HCT116+ch3 and HEC59+ch2 cell lines after PDT as a function
of the optical dose (J cm
72). The optical dose required to induce
cell death in 50% of all cells (IC50) was 0.32+0.03 J cm
72 for the
HCT116+ch2 and 0.39+0.20 J cm
72 for the HCT116+ch3 cells
(P=0.57). Likewise, MSH2-deﬁcient tumour cells showed no altered
sensitivity to PDT. The corresponding IC50-values were
0.54+0.06 J cm
72 for the MMR-deﬁcient HEC59 and
0.46+0.17 J cm
72 for the repair-proﬁcient HEC59+ch2 cells
(P=0.24). Thus, loss of MMR does not result in resistance to PDT.
MMR protein expression in MCF-7 cells after repetitive
PDT exposure
The question was addressed as to whether repetitive treatments
with PDT result in de novo loss of expression of MMR proteins
in the parental human breast cancer MCF-7 cells. These cells
express MLH1, PMS2, MSH2, and MSH6 in amounts that are
readily detectable by immunoblot, and they have previously been
reported to be sensitive to PDT (Hornung et al, 1998). Expression
of MMR proteins in MCF-7 cells after ﬁve subsequent exposures to
PDT and in untreated MCF-7 cells was determined by immunoblot
analyses. Figure 2 shows that MCF-7 cells repeatedly treated with
PDT express parental levels of MLH1, MSH2, MSH6 and PMS2.
The sensitivity of the MCF-7 cells after ﬁve PDT treatments was
similar to that of MCF-7 cells after a single exposure. Therefore,
repeated exposure of tumour cells to PDT does not result in loss
of MMR proteins.
Kinetics of drug uptake and subcellular photosensitiser
distribution
The kinetics of uptake of m-THPC (0.1 mgm l
71) were studied in
the MMR-deﬁcient HCT116+ch2 and -proﬁcient HCT116+ch3
cells by measuring the photosensitiser-mediated ﬂuorescence inten-
sity (counts per pixel, arbitrary unit) as a function of the
incubation time. Figure 3 shows that m-THPC-mediated ﬂuores-
cence intensity markedly increased within 24 h and reached a
plateau with highest ﬂuorescence intensity at 34 h after incubation
in MLH1-proﬁcient as well as in MLH1-deﬁcient cells. Thus, m-
THPC uptake occurs within 24 h and follows similar kinetics in
both cell lines.
The subcellular distribution of m-THPC was analysed by
confocal laser scanning microscopy. m-THPC-mediated ﬂuores-
cence intensity in the cytoplasm of HCT116 cells increased
within 24 h after administration. At that time, only weak ﬂuor-
escence intensity was associated with the nuclear membrane.
Figure 4 represents a typical example of ﬂuorescence distribu-
tion in the HCT116+ch3 (Figure 4A) and HCT116+ch2
(Figure 4B) cell lines after 24 h of m-THPC administration,
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Figure 1 Clonogenic survival curves for PDT for the MLH1-deﬁcient and -proﬁcient colon carcinoma cell lines and the MSH2-deﬁcient and -proﬁcient
endometrial carcinoma cell lines. Each point represents the mean+s.d. of at least three experiments performed in triplicate.
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similar to that of HCT116+ch2 cells. Likewise, longer incubation
with m-THPC resulted in increased ﬂuorescence intensity asso-
ciated with membranous structures in the cytoplasm, whereas
the nucleus did not show detectable ﬂuorescence at any time
after photosensitisation. Thus, drug uptake kinetics and subcel-
lular distributions are very similar in MMR-proﬁcient and
-deﬁcient cells.
DISCUSSION
MLH1 or MSH2-deﬁcient tumour cells have been reported to be
resistant to a large number of anticancer drugs (Aebi et al, 1997;
Fink et al, 1998b) and to radiotherapy (Fritzell et al, 1997; Xu et
al, 2001), and as a result, MMR status may be an important resis-
tance factor. Although loss of MMR results in relatively small
degrees of resistance, there is evidence that this resistance is never-
theless of substantial clinical signiﬁcance. The strongest clinical
evidence correlating chemotherapy responses with the in vitro data
has been reported from studies on ovarian and breast cancers. We
and others (Brown et al, 1997; Fink et al, 1998a; Samimi et al,
2000) have shown that there is an increase in the number of ovar-
ian tumour cells that score negative for MLH1 expression following
platinum-based chemotherapy when compared with untreated
tumours. Recently, studies have correlated tumour response and
poor disease-free survival with loss of MLH1 expression in breast
cancer tumours following anthracycline-based neoadjuvant
chemotherapy (Mackay et al, 2000). These observations support
the concept of in vivo enrichment of a subpopulation of MMR-
deﬁcient cells in response to treatment, which are more likely to
be drug resistant, have a mutator phenotype and consequently,
an adverse effect on prognosis. Similarly, it has been reported that
low levels of MLH1 and MSH2 in malignant gliomas correlate with
resistance to temozolomide, a methylating agent (Friedman et al,
1998).
PDT is a relatively new treatment modality for malignant
tumours. Selective tumour cell necrosis is induced by a distinct
photochemical mechanism. While chemoresistance in MMR-deﬁ-
cient tumours seems to force physicians to surrender an
efﬁcient anticancer treatment, the present study suggests that
PDT might offer a future treatment option for these patients.
So far, it has been reported that PDT does not induce resistance
to chemo- or radiotherapy, and that this treatment can be
repeated without increasing toxicity and with low probability of
inducing resistance to PDT (Sharkey et al, 1993; Luna et al,
1995; Hornung et al, 1998; Singh et al, 2001). Our study extends
the theoretical advantages to conventional treatment modalities
for cancer by demonstrating that loss of MMR does not result
in resistance to PDT.
Loss of MMR has been reported in tumour cells selected by
repeated treatments with cisplatin, methylating agents or doxorubi-
cin (Aebi et al, 1996; Brown et al, 1997). Therefore, we analysed by
immunoblot the presence of the MMR proteins in MCF-7 cells that
survived ﬁve subsequent cycles of PDT. As shown in Figure 2, the
PDT-treated MCF-7 cells expressed parental levels of MLH1,
MSH2, MSH6 and PMS2. Thus, PDT is not only effective against
MMR-deﬁcient cells but - unlike some chemotherapeutic agents –
it does not result in loss of MMR, allowing standard chemo- or
radiotherapy following PDT-mediated tumour treatment.
PDT-induced cell killing is not fully understood and may
depend on the photosensitiser and the treatment protocol used.
However, the potential of PDT to induce genotoxic damage seems
to be relatively low compared with ionising radiation or
chemotherapy (Evans et al, 1997). This may, in part, be explained
as follows. As demonstrated in Figure 4, the cationic and lipophilic
photosensitiser m-THPC localises in cellular membranes, mainly in
the mitochondria with highly negative electrochemical potential of
the inner membrane, and to a lower extent in the nuclear
membrane. Singlet oxygen, the major mediator of the PDT-
induced photochemical reaction (Henderson and Dougherty,
1992), has a very short diffusion distance of 0.01 mm and a very
short lifetime of 0.01 ms (Moan and Berg, 1991). The photochemi-
cal reaction may therefore reach only DNA that is located very
close to the nuclear membrane (Evans et al, 1997). Oxidative
damage leading to single-strand breaks and alkali-labile sites,
DNA-protein crosslinks and DNA degradation, as well as to chro-
mosome aberrations has been reported (Evans et al, 1997; Oleinick
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Figure 2 Immunoblot of untreated MCF-7 cells (ut) and MCF-7 cells
after ﬁve subsequent PDT exposures (PDT). MCF-7 cells repeatedly trea-
ted with PDT express parental levels of MLH1, MSH2, MSH6 and PMS2.
b-tubulin was used as a loading control.
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Figure 3 Photosensitiser-mediated ﬂuorescence intensity (counts per
pixel, cpp) for MLH1-deﬁcient and -proﬁcient tumour cells shown as a
function of incubation time. Each point represents the mean+s.d. of six
experiments.
Figure 4 Bright ﬁeld image of HCT116+ch3 (A) and HCT116+ch2 (B)
after incubation with 0.1 mgm l
71 m-THPC for 24 h. After 24 h of incuba-
tion there was no detectable ﬂuorescence within the nucleus. The nuclear
membrane is distinctly stained in both cell lines.
Photodynamic therapy and DNA mismatch repair
VA Schwarz et al
1133
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1130–1135and Evans, 1998). These lesions, however, are likely to be relatively
easily repaired (McNair et al, 1997). Considering that MMR seems
not to be affected by PDT, it is reasonable to assume that PDT-
induced DNA damage remains of low clinical importance. Indeed,
the risk of PDT generating secondary cancer is known to be very
small (Moan and Berg, 1992).
In order to ensure that PDT acts similarly in MMR-proﬁcient
and -deﬁcient tumour cells, the subcellular photosensitiser distribu-
tion and kinetics of drug uptake (i.e. relative values representing
changes in drug concentrations) have been estimated using ﬂuores-
cence microscopy. As demonstrated in Figures 3 and 4, both, drug
uptake kinetics and drug distribution, were similar in MMR-proﬁ-
cient and -deﬁcient cells. This ﬁnding further supports the idea
that PDT-mediated cell killing is fully independent of MMR.
Furthermore, the pattern of the subcellular photosensitiser distri-
bution and the kinetics of drug uptake in HCT116 cells are in
good agreement with previous ﬁndings of this laboratory in
MCF-7 and V-79 cells that are known to be proﬁcient in MMR
(Hornung et al, 1997).
The addition of mitomycin C has been shown to enhance the
PDT effect (Nahabedian et al, 1988). Recently, it has been reported
that loss of MMR is speciﬁcally associated with hypersensitivity to
mitomycin C (Fiumicino et al, 2000). Although mechanistic studies
are needed to fully elucidate the biochemical events involved, these
ﬁndings are interesting because they may suggest a means of selec-
tively eliminating cells that have lost their ability to perform MMR.
In conclusion, our results demonstrate that: (i) PDT is as efﬁ-
cient in MMR-deﬁcient cells as in MMR-proﬁcient cells; (ii)
repetitive treatments with PDT do not result in loss of MMR;
and (iii) MMR-deﬁcient cells show similar m-THPC distribution
and kinetics of drug uptake as cells proﬁcient in MMR. Thus,
our results suggest the use of PDT as a strategy for circumventing
resistance due to loss of MMR.
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